Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

SAP and Lessons Learned from a Primary Immunodeficiency

Jennifer L. Cannons and Pamela L. Schwartzberg
J Immunol September 1, 2017, 199 (5) 1531-1533; DOI: https://doi.org/10.4049/jimmunol.1701007
Jennifer L. Cannons
Genetic Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pamela L. Schwartzberg
Genetic Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pamela L. Schwartzberg
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Approximately 19 years ago, Terhorst and colleagues (1) reported the cloning of the gene encoding a small adaptor protein, signaling lymphocyte activation molecule (SLAM)-associated protein (SAP), named by virtue of its binding to the intracellular tail of the cell surface receptor SLAM. Genetic mapping, along with two independent studies using positional cloning approaches (2, 3), revealed that this gene, now known as SH2D1a, was mutated in X-linked lymphoproliferative syndrome (XLP)1, a rare primary immunodeficiency characterized by fulminant mononucleosis triggered by EBV. The study of SAP and the associated SLAM family members has led to multiple discoveries about the genetic immunodeficiency XLP1, as well as insight into the biology of lymphocyte–lymphocyte interactions, regulation of germinal center (GC) formation, requirements for cytolysis of B cells, development of invariant NKT (iNKT) cells, and induction of T cell restimulation-induced cell death (4–6). Moreover, recent studies of SAP-independent functions of the SLAM family members have identified novel roles for these receptors in immune cell homeostasis and pattern recognition (7–9).

XLP1 was first described in the 1970s as a fatal immunodeficiency characterized by lymphoproliferation, hemophagocytosis, and abnormal Ab levels (10). Although such patients initially appear healthy, they are unable to clear EBV, with fatal infectious mononucleosis resulting in most cases. XLP1 is a noteworthy example of a primary immunodeficiency characterized by susceptibility mainly to one infectious agent; however, the findings of lymphoproliferation, lymphomas, and altered serum Igs even in the absence of EBV infection argued that these patients have a broader immune dysfunction (4, 5, 11). The cloning of SH2D1a allowed identification of other family members with XLP1 and generation of mouse models, thereby providing further insight into this disease and the role of SAP and SLAM family members in immune cell function and homeostasis.

SLAM was first cloned as a T cell costimulatory receptor that influenced patterns of T cell IFN-γ production (12). SLAM is now recognized as a member of a larger family of receptors, including 2B4 (SLAMF4, CD244), LY9 (SLAMF3, CD229), CD84 (SLAMF5), NTB-A/Ly108 (SLAMF6, CD352), and CRACC (SLAMF7, CD319). With the exception of 2B4, the SLAM family members are homophilic (i.e., self-ligands), many of which function as cytolytic receptors on NK and CD8+ T cells. A larger family of receptors has homology to this superfamily and includes CD2 and CD48 (SLAMF2, the ligand for 2B4), although not all of these receptors bind SAP, which is expressed mainly in T and NK cells (5, 6); some B cell expression has also been reported (13).

One of the most striking features of SAP is that it consists primarily of one Src homology 2 domain: Src homology 2 domains are conserved domains that bind to phosphotyrosine-based motifs and are usually part of larger proteins, including multimodular domain adaptors and enzymes (14). Surprisingly, SAP binds to a tyrosine-based motif on SLAM in the absence of phosphorylation, although binding improves upon phosphorylation, and binding to other SLAM family receptors does require tyrosine phosphorylation (15, 16). So how does SAP help transmit signals from these receptors? In this landmark study, Terhorst and colleagues hypothesized that SAP functions by blocking the recruitment of phosphatases (1), in part due to the similarity of its binding site to immunotyrosine inhibitory motifs. They further showed using overexpression in heterologous cells that SAP can compete with the phosphatase SHP2. However, subsequent data from Veillette and colleagues (17), as well as from Terhorst, Eck, and colleagues (18), provided contrasting evidence that SAP functions as an adaptor molecule, binding to the Fyn SH3 domain. Other evidence demonstrated that SAP also binds Lck (19, 20). Taken together, these data supported a model in which SAP functions as an adaptor molecule required for recruiting Src family kinases, leading to phosphorylation and transmission of positive signals downstream of SLAM family receptors. Nonetheless, an increasing body of data now supports both pathways, demonstrating that SAP can also compete for binding of inhibitory molecules such as SHP1, SHP2, and SHIP to multiple SLAM family members (21–24). Thus, SAP appears to function as a switch that determines whether SLAM family members transmit positive signals (if SAP is present) or function as inhibitory receptors (in the absence of SAP). This model was first put forth by Sidorenko and colleagues (25, 26) when they proposed that the SAP binding motif be called an immunotyrosine switch motif, and was supported by early work on 2B4 (21).

So how does SAP affect immune cell function? Even prior to the cloning of SAP, NK cells from XLP1 patients were found to exhibit impaired killing (27). Subsequent data demonstrated that CD8+ T cells from XLP1 patients were unable to kill EBV-infected B cell targets (28–30), suggesting a reason why XLP1 patients fail to clear EBV. Yet other data suggested that the SLAM family member 2B4 inhibited target cell killing in the absence of SAP, supporting the idea of SLAM family members as inhibitory receptors (31–33). More recently, SAP-deficient T cells have been found to exhibit defective restimulation-induced cell death, again as a result of inhibitory activity of a SLAM family member, NTB-A; this may contribute to the lymphoproliferation seen in XLP1 (34).

Evaluation of SAP-deficient mice has highlighted several additional phenotypes, and these have helped provide insight into the mechanistic underpinnings of XLP1. First, based on the connection with Fyn, which affects iNKT cell development, SAP-deficient mice were shown to have a severe block in iNKT cell development (35–37). A dearth of NKT cells, even in the absence of EBV infection, is now recognized as a feature of XLP1. Second, challenge with infectious agents or immunization revealed that SAP deficiency leads to profound defects in long-term humoral immunity and the generation of memory IgG B cells (38) that are associated with impaired GC formation (39). Additional data from mice demonstrated that the humoral immune defect is primarily T cell intrinsic (39, 40) [although in some genetic backgrounds, e.g., BALB/c, B cell contributions have also been shown (13)]. Accordingly, SAP-deficient mice have been used in myriad studies that have helped uncover requirements for T cell help in B cell GC formation, including many studies of follicular Th cells (5, 41). Interestingly, a lack of GCs was noted in some of the earliest XLP1 studies (10); however, the detailed mechanistic findings in mice, as well as subsequent evaluation in larger numbers of XLP1 patients (11), clarified that humoral defects are a key feature of this disorder.

Intravital microscopy in mice, complemented by in vitro assays, together have provided further insight into these phenotypes, revealing that SAP-deficient T cells exhibit a defect in stable conjugation to B cells, despite relatively normal interactions with dendritic cells (42). This defect likely accounts for the inability of SAP-deficient T cells to deliver contact-dependent cognate help for GC formation. Importantly, these observations helped crystallize an appreciation that defective lymphocyte–lymphocyte interactions provide a common pathophysiological mechanism for the phenotypes associated with SAP deficiency (43). Thus, in XLP1, CD8+ T cells and NK cells are activated but fail to effectively kill EBV-infected B cells, CD4+ T cells are activated but fail to provide cognate help for B cells for GC formation, and NKT cells (which are selected by interactions with double-positive thymocytes) fail to develop. Indeed, the occurrence of B cell lymphomas, which can be EBV− in XLP1, suggests a basic defect in immunosurveillance of B cell malignancies.

So why are these defects specific for B cells (and other hematopoietic cells)? Clues came from expression of SLAM family members, which are expressed primarily on hematopoietic cells, and at very high levels on activated B cells. Indeed, CD48, the ligand for 2B4, was first described as a marker that was highly induced on B cells by EBV infection (44). Thus, in the absence of SAP, strong inhibitory signals from SLAM family members (particularly 2B4 and Ly108/NTB-A) are triggered by EBV-infected B cells, thereby preventing effective T cell activation and killing of B cell targets. Other data suggest that SAP is important for regulating killing of hematopoietic targets in general (6). It is notable that many of the phenotypes associated with SAP deficiency require the presence of a SLAM family member to transmit an inhibitory signal, a fundamentally different mechanism of signaling than when SAP acts as an adaptor. The strongest data supporting this interpretation include those showing that blocking or mutation of SLAM family members improved phenotypes associated with SAP deficiency, such as killing of B cell targets (24, 29, 30), and the demonstration that deficiency in Ly108 markedly improved the GC and iNKT cell developmental defects in SAP-deficient mice (45). The strong inhibitory effects of these receptors in the absence of SAP, combined with their roles in transmitting both positive and negative signals, may account for why deficiencies of SLAM receptors do not recapitulate many features associated with SAP deficiency.

Nonetheless, studies of the SLAM family have also been revealing about lymphocyte biology. The SLAM family receptors are encoded in a polymorphic gene cluster on mouse and human chromosome 1 that has been linked to autoimmunity in both species. Interestingly, polymorphisms in specific SLAM family members have been implicated in the development of autoantibodies in the lupus-prone mouse strains, supporting the roles of these receptors in regulating humoral immunity (46). Similarly, variation in NKT cell numbers in various strains of mice has also been linked to the SLAM family locus (47). But also fascinating is growing evidence for SAP-independent functions of SLAM family members as pattern recognition receptors, particularly in myeloid cells, where SLAM has been found to bind to the outer membrane protein of Escherichia coli and other Gram-negative bacteria (7). SLAM also serves as a receptor for measles virus (48). More recent data have implicated CRACC (SLAMF7) as a CD47-independent “eat-me” signal that helps clear dying cells (9). Thus, the SLAM family members are now recognized as regulators of multiple aspects of both immune activation and homeostasis.

These studies of SAP and SLAM family members have helped uncover many new insights into lymphocyte interactions and immune cell biology, most of which were triggered by findings in this featured study from the Terhorst laboratory (1). Together, this work provides an excellent example of how the identification of genes implicated in primary immunodeficiencies has spurred not only knowledge of the disease, but also helped uncover new insights into the workings of the immune system.

Disclosures

The authors have no financial conflicts of interest.

Footnotes

  • Abbreviations used in this article:

    GC
    germinal center
    iNKT
    invariant NKT
    SAP
    SLAM-associated protein
    SLAM
    signaling lymphocyte activation molecule
    XLP
    X-linked lymphoproliferative syndrome.

References

  1. ↵
    1. Sayos, J.,
    2. C. Wu,
    3. M. Morra,
    4. N. Wang,
    5. X. Zhang,
    6. D. Allen,
    7. S. van Schaik,
    8. L. Notarangelo,
    9. R. Geha,
    10. M. G. Roncarolo, et al
    . 1998. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 395: 462–469.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Coffey, A. J.,
    2. R. A. Brooksbank,
    3. O. Brandau,
    4. T. Oohashi,
    5. G. R. Howell,
    6. J. M. Bye,
    7. A. P. Cahn,
    8. J. Durham,
    9. P. Heath,
    10. P. Wray, et al
    . 1998. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat. Genet. 20: 129–135.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Nichols, K. E.,
    2. D. P. Harkin,
    3. S. Levitz,
    4. M. Krainer,
    5. K. A. Kolquist,
    6. C. Genovese,
    7. A. Bernard,
    8. M. Ferguson,
    9. L. Zuo,
    10. E. Snyder, et al
    . 1998. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc. Natl. Acad. Sci. USA 95: 13765–13770.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Calpe, S.,
    2. N. Wang,
    3. X. Romero,
    4. S. B. Berger,
    5. A. Lanyi,
    6. P. Engel,
    7. C. Terhorst
    . 2008. The SLAM and SAP gene families control innate and adaptive immune responses. Adv. Immunol. 97: 177–250.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Cannons, J. L.,
    2. S. G. Tangye,
    3. P. L. Schwartzberg
    . 2011. SLAM family receptors and SAP adaptors in immunity. Annu. Rev. Immunol. 29: 665–705.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Wu, N.,
    2. A. Veillette
    . 2016. SLAM family receptors in normal immunity and immune pathologies. Curr. Opin. Immunol. 38: 45–51.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Berger, S. B.,
    2. X. Romero,
    3. C. Ma,
    4. G. Wang,
    5. W. A. Faubion,
    6. G. Liao,
    7. E. Compeer,
    8. M. Keszei,
    9. L. Rameh,
    10. N. Wang, et al
    . 2010. SLAM is a microbial sensor that regulates bacterial phagosome functions in macrophages. Nat. Immunol. 11: 920–927.
    OpenUrlCrossRefPubMed
    1. Howie, D.,
    2. F. S. Laroux,
    3. M. Morra,
    4. A. R. Satoskar,
    5. L. E. Rosas,
    6. W. A. Faubion,
    7. A. Julien,
    8. S. Rietdijk,
    9. A. J. Coyle,
    10. C. Fraser,
    11. C. Terhorst
    . 2005. Cutting edge: the SLAM family receptor Ly108 controls T cell and neutrophil functions. J. Immunol. 174: 5931–5935.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Chen, J.,
    2. M. C. Zhong,
    3. H. Guo,
    4. D. Davidson,
    5. S. Mishel,
    6. Y. Lu,
    7. I. Rhee,
    8. L.A. Pérez-Quintero,
    9. S. Zhang,
    10. M. E. Cruz-Munoz, et al
    . 2017. SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin. Nature 544: 493–497.
    OpenUrl
  9. ↵
    1. Purtilo, D. T.,
    2. C. K. Cassel,
    3. J. P. Yang,
    4. R. Harper
    . 1975. X-linked recessive progressive combined variable immunodeficiency (Duncan’s disease). Lancet 1: 935–940.
    OpenUrlPubMed
  10. ↵
    1. Tangye, S. G.
    2014. XLP: clinical features and molecular etiology due to mutations in SH2D1A encoding SAP. J. Clin. Immunol. 34: 772–779.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Cocks, B. G.,
    2. C. C. Chang,
    3. J. M. Carballido,
    4. H. Yssel,
    5. J. E. de Vries,
    6. G. Aversa
    . 1995. A novel receptor involved in T-cell activation. Nature 376: 260–263.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Morra, M.,
    2. R. A. Barrington,
    3. A. C. Abadia-Molina,
    4. S. Okamoto,
    5. A. Julien,
    6. C. Gullo,
    7. A. Kalsy,
    8. M. J. Edwards,
    9. G. Chen,
    10. R. Spolski, et al
    . 2005. Defective B cell responses in the absence of SH2D1A. Proc. Natl. Acad. Sci. USA 102: 4819–4823.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Pawson, T.,
    2. P. Nash
    . 2000. Protein–protein interactions define specificity in signal transduction. Genes Dev. 14: 1027–1047.
    OpenUrlFREE Full Text
  14. ↵
    1. Poy, F.,
    2. M. B. Yaffe,
    3. J. Sayos,
    4. K. Saxena,
    5. M. Morra,
    6. J. Sumegi,
    7. L. C. Cantley,
    8. C. Terhorst,
    9. M. J. Eck
    . 1999. Crystal structures of the XLP protein SAP reveal a class of SH2 domains with extended, phosphotyrosine-independent sequence recognition. Mol. Cell 4: 555–561.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Li, S.C.,
    2. G. Gish,
    3. D. Yang,
    4. A. J. Coffey,
    5. J. D. Forman-Kay,
    6. I. Ernberg,
    7. L. E. Kay,
    8. T. Pawson
    . 1999. Novel mode of ligand binding by the SH2 domain of the human XLP disease gene product SAP/SH2D1A. Curr. Biol. 9: 1355–1362.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Latour, S.,
    2. R. Roncagalli,
    3. R. Chen,
    4. M. Bakinowski,
    5. X. Shi,
    6. P. L. Schwartzberg,
    7. D. Davidson,
    8. A. Veillette
    . 2003. Binding of SAP SH2 domain to FynT SH3 domain reveals a novel mechanism of receptor signalling in immune regulation. Nat. Cell Biol. 5: 149–154.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Chan, B.,
    2. A. Lanyi,
    3. H. K. Song,
    4. J. Griesbach,
    5. M. Simarro-Grande,
    6. F. Poy,
    7. D. Howie,
    8. J. Sumegi,
    9. C. Terhorst,
    10. M. J. Eck
    . 2003. SAP couples Fyn to SLAM immune receptors. Nat. Cell Biol. 5: 155–160.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Howie, D.,
    2. M. Simarro,
    3. J. Sayos,
    4. M. Guirado,
    5. J. Sancho,
    6. C. Terhorst
    . 2002. Molecular dissection of the signaling and costimulatory functions of CD150 (SLAM): CD150/SAP binding and CD150-mediated costimulation. Blood 99: 957–965.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Katz, G.,
    2. S. M. Krummey,
    3. S. E. Larsen,
    4. J. R. Stinson,
    5. A. L. Snow
    . 2014. SAP facilitates recruitment and activation of LCK at NTB-A receptors during restimulation-induced cell death. J. Immunol. 192: 4202–4209.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Tangye, S. G.,
    2. S. Lazetic,
    3. E. Woollatt,
    4. G. R. Sutherland,
    5. L. L. Lanier,
    6. J. H. Phillips
    . 1999. Cutting edge: human 2B4, an activating NK cell receptor, recruits the protein tyrosine phosphatase SHP-2 and the adaptor signaling protein SAP. J. Immunol. 162: 6981–6985.
    OpenUrlAbstract/FREE Full Text
    1. Eissmann, P.,
    2. L. Beauchamp,
    3. J. Wooters,
    4. J. C. Tilton,
    5. E. O. Long,
    6. C. Watzl
    . 2005. Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244). Blood 105: 4722–4729.
    OpenUrlAbstract/FREE Full Text
    1. Dong, Z.,
    2. D. Davidson,
    3. L.A. Pérez-Quintero,
    4. T. Kurosaki,
    5. W. Swat,
    6. A. Veillette
    . 2012. The adaptor SAP controls NK cell activation by regulating the enzymes Vav-1 and SHIP-1 and by enhancing conjugates with target cells. Immunity 36: 974–985.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Zhao, F.,
    2. J. L. Cannons,
    3. M. Dutta,
    4. G. M. Griffiths,
    5. P. L. Schwartzberg
    . 2012. Positive and negative signaling through SLAM receptors regulate synapse organization and thresholds of cytolysis. Immunity 36: 1003–1016.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Shlapatska, L. M.,
    2. S. V. Mikhalap,
    3. A. G. Berdova,
    4. O. M. Zelensky,
    5. T. J. Yun,
    6. K. E. Nichols,
    7. E. A. Clark,
    8. S. P. Sidorenko
    . 2001. CD150 association with either the SH2-containing inositol phosphatase or the SH2-containing protein tyrosine phosphatase is regulated by the adaptor protein SH2D1A. J. Immunol. 166: 5480–5487.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Sidorenko, S. P.,
    2. E. A. Clark
    . 2003. The dual-function CD150 receptor subfamily: the viral attraction. Nat. Immunol. 4: 19–24.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Sullivan, J. L.,
    2. K. S. Byron,
    3. F. E. Brewster,
    4. D. T. Purtilo
    . 1980. Deficient natural killer cell activity in x-linked lymphoproliferative syndrome. Science 210: 543–545.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Dupré, L.,
    2. G. Andolfi,
    3. S. G. Tangye,
    4. R. Clementi,
    5. F. Locatelli,
    6. M. Aricò,
    7. A. Aiuti,
    8. M.G. Roncarolo
    . 2005. SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells. Blood 105: 4383–4389.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Hislop, A. D.,
    2. U. Palendira,
    3. A. M. Leese,
    4. P. D. Arkwright,
    5. P. S. Rohrlich,
    6. S. G. Tangye,
    7. H. B. Gaspar,
    8. A. C. Lankester,
    9. A. Moretta,
    10. A. B. Rickinson
    . 2010. Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets. Blood 116: 3249–3257.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Palendira, U.,
    2. C. Low,
    3. A. Chan,
    4. A. D. Hislop,
    5. E. Ho,
    6. T. G. Phan,
    7. E. Deenick,
    8. M. C. Cook,
    9. D. S. Riminton,
    10. S. Choo, et al
    . 2011. Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP. PLoS Biol. 9: e1001187.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Parolini, S.,
    2. C. Bottino,
    3. M. Falco,
    4. R. Augugliaro,
    5. S. Giliani,
    6. R. Franceschini,
    7. H. D. Ochs,
    8. H. Wolf,
    9. J.-Y. Bonnefoy,
    10. R. Biassoni, et al
    . 2000. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J. Exp. Med. 192: 337–346.
    OpenUrlAbstract/FREE Full Text
    1. Nakajima, H.,
    2. M. Cella,
    3. A. Bouchon,
    4. H. L. Grierson,
    5. J. Lewis,
    6. C. S. Duckett,
    7. J. I. Cohen,
    8. M. Colonna
    . 2000. Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity. Eur. J. Immunol. 30: 3309–3318.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Tangye, S. G.,
    2. J. H. Phillips,
    3. L. L. Lanier,
    4. K. E. Nichols
    . 2000. Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome. J. Immunol. 165: 2932–2936.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Snow, A. L.,
    2. R. A. Marsh,
    3. S. M. Krummey,
    4. P. Roehrs,
    5. L. R. Young,
    6. K. Zhang,
    7. J. van Hoff,
    8. D. Dhar,
    9. K. E. Nichols,
    10. A. H. Filipovich, et al
    . 2009. Restimulation-induced apoptosis of T cells is impaired in patients with X-linked lymphoproliferative disease caused by SAP deficiency. J. Clin. Invest. 119: 2976–2989.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Nichols, K. E.,
    2. J. Hom,
    3. S.Y. Gong,
    4. A. Ganguly,
    5. C. S. Ma,
    6. J. L. Cannons,
    7. S. G. Tangye,
    8. P. L. Schwartzberg,
    9. G. A. Koretzky,
    10. P. L. Stein
    . 2005. Regulation of NKT cell development by SAP, the protein defective in XLP. Nat. Med. 11: 340–345.
    OpenUrlCrossRefPubMed
    1. Chung, B.,
    2. A. Aoukaty,
    3. J. Dutz,
    4. C. Terhorst,
    5. R. Tan
    . 2005. Signaling lymphocytic activation molecule-associated protein controls NKT cell functions. J. Immunol. 174: 3153–3157.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Pasquier, B.,
    2. L. Yin,
    3. M.C. Fondanèche,
    4. F. Relouzat,
    5. C. Bloch-Queyrat,
    6. N. Lambert,
    7. A. Fischer,
    8. G. de Saint-Basile,
    9. S. Latour
    . 2005. Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product. J. Exp. Med. 201: 695–701.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Czar, M. J.,
    2. E. N. Kersh,
    3. L. A. Mijares,
    4. G. Lanier,
    5. J. Lewis,
    6. G. Yap,
    7. A. Chen,
    8. A. Sher,
    9. C. S. Duckett,
    10. R. Ahmed,
    11. P. L. Schwartzberg
    . 2001. Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/SAP. Proc. Natl. Acad. Sci. USA 98: 7449–7454.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Crotty, S.,
    2. E. N. Kersh,
    3. J. Cannons,
    4. P. L. Schwartzberg,
    5. R. Ahmed
    . 2003. SAP is required for generating long-term humoral immunity. Nature 421: 282–287.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Cannons, J. L.,
    2. L. J. Yu,
    3. D. Jankovic,
    4. S. Crotty,
    5. R. Horai,
    6. M. Kirby,
    7. S. Anderson,
    8. A. W. Cheever,
    9. A. Sher,
    10. P. L. Schwartzberg
    . 2006. SAP regulates T cell-mediated help for humoral immunity by a mechanism distinct from cytokine regulation. J. Exp. Med. 203: 1551–1565.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Crotty, S.
    2011. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29: 621–663.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Qi, H.,
    2. J. L. Cannons,
    3. F. Klauschen,
    4. P. L. Schwartzberg,
    5. R. N. Germain
    . 2008. SAP-controlled T–B cell interactions underlie germinal centre formation. Nature 455: 764–769.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Schwartzberg, P. L.,
    2. K. L. Mueller,
    3. H. Qi,
    4. J. L. Cannons
    . 2009. SLAM receptors and SAP influence lymphocyte interactions, development and function. Nat. Rev. Immunol. 9: 39–46.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Thorley-Lawson, D. A.,
    2. R. T. Schooley,
    3. A. K. Bhan,
    4. L. M. Nadler
    . 1982. Epstein-Barr virus superinduces a new human B cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts. Cell 30: 415–425.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Kageyama, R.,
    2. J. L. Cannons,
    3. F. Zhao,
    4. I. Yusuf,
    5. C. Lao,
    6. M. Locci,
    7. P. L. Schwartzberg,
    8. S. Crotty
    . 2012. The receptor Ly108 functions as a SAP adaptor-dependent on-off switch for T cell help to B cells and NKT cell development. Immunity 36: 986–1002.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Chan, A. Y.,
    2. J. M. Westcott,
    3. J. M. Mooney,
    4. E. K. Wakeland,
    5. J. D. Schatzle
    . 2006. The role of SAP and the SLAM family in autoimmunity. Curr. Opin. Immunol. 18: 656–664.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Rocha-Campos, A.C.,
    2. R. Melki,
    3. R. Zhu,
    4. N. Deruytter,
    5. D. Damotte,
    6. M. Dy,
    7. A. Herbelin,
    8. H.J. Garchon
    . 2006. Genetic and functional analysis of the Nkt1 locus using congenic NOD mice: improved Vα14-NKT cell performance but failure to protect against type 1 diabetes. Diabetes 55: 1163–1170.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Tatsuo, H.,
    2. N. Ono,
    3. K. Tanaka,
    4. Y. Yanagi
    . 2000. SLAM (CDw150) is a cellular receptor for measles virus. Nature 406: 893–897.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Immunology: 199 (5)
The Journal of Immunology
Vol. 199, Issue 5
1 Sep 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Advertising (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
SAP and Lessons Learned from a Primary Immunodeficiency
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
SAP and Lessons Learned from a Primary Immunodeficiency
Jennifer L. Cannons, Pamela L. Schwartzberg
The Journal of Immunology September 1, 2017, 199 (5) 1531-1533; DOI: 10.4049/jimmunol.1701007

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
SAP and Lessons Learned from a Primary Immunodeficiency
Jennifer L. Cannons, Pamela L. Schwartzberg
The Journal of Immunology September 1, 2017, 199 (5) 1531-1533; DOI: 10.4049/jimmunol.1701007
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Conceiving the Inconceivable: The Function of Aire in Immune Tolerance to Peripheral Tissue-Restricted Antigens in the Thymus
  • Glial Cells as Regulators of Neuroimmune Interactions in the Central Nervous System
  • The Colon as a Major Site of Immunoregulation by CD4+ T Cell Subsets in the Steady State
Show more PILLARS OF IMMUNOLOGY

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • Public Access
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2021 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606